News for Xlife Sciences AG (XLS.DE)

Xlife Sciences AG / Key word(s): Half Year Results/Interim Report Xlife Sciences AG: Successful First Half of 2024 with Strategic Progr...

Xlife Sciences AG / Key word: Alliance/Merger Xlife Sciences AG Announces Strategic Merger Between palleos healthcare GmbH and OCT Clinical GmbH 27.05.2024 / 07:00...

Xlife Sciences AG / Key word: Annual Results Xlife Sciences AG Publishes 2023 Annual Report 23-Apr-2024 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The...

Xlife Sciences AG / Key word: Alliance/Letter of Intent Xlife Sciences AG Expands Collaboration with Department of Health Abu Dhabi, Partners with Thermo Fisher Scientific and...

Xlife Sciences AG / Key word: Mergers & Acquisitions/Takeover VERAXA Biotech AG acquires Synimmune GmbH to expand cancer pipeline 29-Dec-2023 / 17:45 CET/CEST Release of an ad hoc...

Xlife Sciences AG / Key word: Half Year Results Xlife Sciences with significant progress in H1 2023 21-Sep-2023 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art....

Xlife Sciences AG / Key word: Strategic Company Decision Collaboration of Xlife Sciences and the Department of Health – Abu Dhabi to drive global innovations in the life sciences... -Today at 03:47 am- MarketScreener

Xlife Sciences AG / Key word: AGMEGM Xlife Sciences publishes agenda for Annual General Meeting 2023 26-May-2023 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The... | May 26, 2023

Xlife Sciences AG / Key word: Miscellaneous/Regulatory Approval saniva diagnostics receives approval from the US FDA for its medical product NeuroMex 16-Feb-2023 / 07:00 CET/CEST Release of an... | February 16, 2023

Xlife Sciences AG / Key word: Miscellaneous Stifel initiates research coverage of Xlife Sciences 23.01.2023 / 07:00 CET/CEST   The renowned investment bank Stifel commenced... | January 23, 2023

DGAP-Ad-hoc: Xlife Sciences AG / Key word: Research Update Xlife Sciences AG : Antiviral drug candidate 17-Feb-2021 / 06:44 CET/CEST Disclosure of an inside information acc. to Article 17 MAR...

License Deal of 300 million euros successfully completed ...